Values as of: 2024-10-30
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 227.89Change
-4.51 (-1.94)%Market Cap
USD 23.48BVolume
1.61MAnalyst Target
USD 199.20Verdict
Verdict
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Company Website : https://www.iconplc.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| IDXX | IDEXX Laboratories Inc |
+3.25 (+0.73%) |
USD 37.69B |
| ILMN | Illumina Inc |
+1.66 (+1.14%) |
USD 22.77B |
| NTRA | Natera Inc |
+1.99 (+1.60%) |
USD 14.84B |
| EXAS | EXACT Sciences Corporation |
+0.82 (+1.18%) |
USD 12.84B |
| MEDP | Medpace Holdings Inc |
-11.41 (-3.46%) |
USD 10.15B |
| RDNT | RadNet Inc |
-0.94 (-1.39%) |
USD 4.95B |
| SHC | Sotera Health Co |
-0.09 (-0.57%) |
USD 4.39B |
| NEOG | Neogen Corporation |
+0.23 (+1.60%) |
USD 2.98B |
| GH | Guardant Health Inc |
+1.28 (+5.87%) |
USD 2.52B |
| VCYT | Veracyte Inc |
+0.62 (+1.80%) |
USD 2.50B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| IRESF | iShares Public Limited Co.. | 19.90 % | 0.00 % |
N/A |
N/A |
| EIRL | iShares MSCI Ireland ETF | 16.40 % | 0.47 % |
-0.13 (-1.01%) |
USD 0.08B |
| PCIG | Litman Gregory Funds Trus.. | 10.24 % | 0.00 % |
-0.10 (-1.01%) |
USD 0.03B |
| XGES:LSE | Xtrackers MSCI Genomic He.. | 4.62 % | 0.00 % |
+0.09 (+-1.01%) |
N/A |
| BBH | VanEck Biotech ETF | 4.59 % | 0.35 % |
-0.05 (-1.01%) |
USD 0.45B |
| XGEN:XETRA | Xtrackers MSCI Genomic He.. | 4.57 % | 0.00 % |
-0.04 (-1.01%) |
N/A |
| W311:XETRA | HAN-GINS Indxx Healthcare.. | 4.30 % | 0.00 % |
-0.06 (-1.01%) |
USD 0.02B |
| W311:F | HAN-GINS Indxx Healthcare.. | 4.30 % | 0.00 % |
-0.08 (-1.01%) |
USD 0.02B |
| WELL:PA | HAN-GINS Indxx Healthcare.. | 4.30 % | 0.00 % |
-0.09 (-1.01%) |
N/A |
| WELL:SW | HAN-GINS Indxx Healthcare.. | 4.30 % | 0.00 % |
-0.01 (-1.01%) |
N/A |
| QQQN | VictoryShares Nasdaq Next.. | 2.29 % | 0.00 % |
N/A |
USD 0.02B |
| QQJE:CA | Invesco ESG NASDAQ Next G.. | 1.97 % | 0.00 % |
+0.34 (+-1.01%) |
CAD 1.02M |
| QQJG | Invesco ESG NASDAQ Next G.. | 1.96 % | 0.00 % |
-0.20 (-1.01%) |
USD 5.87M |
| EQQJ:LSE | Invesco NASDAQ Next Gener.. | 1.83 % | 0.00 % |
-0.23 (-1.01%) |
N/A |
| EQQJ:SW | Invesco NASDAQ Next Gener.. | 1.78 % | 0.00 % |
N/A |
N/A |
| JNDQ:AU | BETAJNDQ ETF UNITS | 1.77 % | 0.00 % |
-0.01 (-1.01%) |
N/A |
| EQQJ:XETRA | Invesco NASDAQ Next Gener.. | 1.54 % | 0.00 % |
-0.31 (-1.01%) |
USD 0.05B |
| QQQJ | Invesco NASDAQ Next Gen 1.. | 1.52 % | 0.00 % |
-0.15 (-1.01%) |
USD 0.68B |
| GNRX | 0.00 % | 0.55 % |
N/A |
N/A | |
| ZGEN:CA | 0.00 % | 0.00 % |
N/A |
N/A | |
| IREMF | 0.00 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -79.87% | 8% | B- | 5% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -79.87% | 8% | B- | 6% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | -77.21% | 12% | F | 5% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -77.21% | 12% | F | 6% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -62.10% | 35% | F | 18% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -62.10% | 35% | F | 19% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 15.86% | 62% | D | 70% | C- | ||
| Dividend Return | 15.86% | 62% | D | 69% | C- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 27.00% | 92% | A | 66% | D+ | ||
| Risk Adjusted Return | 58.76% | 94% | A | 83% | B | ||
| Market Capitalization | 23.48B | 98% | N/A | 96% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
